Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 8, 2007 - Issue 12
Submit an article Journal homepage
179
Views
11
CrossRef citations to date
0
Altmetric
Review

A pharmacogenomic evaluation of migraine therapy

Matthew P Johnson Griffith University, Genomics Research Centre, School of Medical Science, PMB 50 GCMC Gold Coast, Queensland 9726, Australia +61 7 5552 8664; +61 7 5552 9081; [email protected]; Department of Genetics, Southwest Foundation for Biomedical Research, PO Box 760549, San Antonio, TX 78245-0549, USA
, PhD,
Francesca Fernandez Griffith University, Genomics Research Centre, School of Medical Science, PMB 50 GCMC Gold Coast, Queensland 9726, Australia +61 7 5552 8664; +61 7 5552 9081; [email protected]
, PhD,
Natalie J Colson Griffith University, Genomics Research Centre, School of Medical Science, PMB 50 GCMC Gold Coast, Queensland 9726, Australia +61 7 5552 8664; +61 7 5552 9081; [email protected]
, PhD &
Lyn R Griffiths Griffith University, Genomics Research Centre, School of Medical Science, PMB 50 GCMC Gold Coast, Queensland 9726, Australia +61 7 5552 8664; +61 7 5552 9081; [email protected]
, PhD
Pages 1821-1835 | Published online: 14 Aug 2007

Bibliography

  • HEADACHE CLASSIFICATION COMMITTEE OF THE INTERNATIONAL HEADACHE SOCIETY: Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia (1988) 8(Suppl. 7):1-96.
  • HEADACHE CLASSIFICATION SUBCOMMITTEE OF THE INTERNATIONAL HEADACHE SOCIETY: The international classification of headache disorders, 2nd Edition. Cephalalgia (2004) 24(Suppl. 1):1-160.
  • WORLD HEALTH ORGANIZATION: The World Health Report 2001: Mental Health: New Understanding, New Hope. (Ed.), World Health Organization, Geneva (2001):xviii, 178.
  • LANCE JW, GOADSBY PJ: Mechanism and Management of Headache. (Ed.), Butterworth-Heinemann, Oxford (1998):317.
  • PIETROBON D, STRIESSNIG J: Neurobiology of migraine. Nat. Rev. Neurosci. (2003) 4(5):386-398.
  • GOADSBY PJ, LIPTON RB, FERRARI MD: Migraine – current understanding and treatment. N. Engl. J. Med. (2002) 346(4):257-270.
  • STEWART WF, LIPTON RB, CELENTANO DD, REED ML: Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. JAMA (1992) 267(1):64-69.
  • STEWART WF, LIPTON RB, LIBERMAN J: Variation in migraine prevalence by race. Neurology (1996) 47(1):52-59.
  • JOUTEL A, DUCROS A, VAHEDI K et al.: Genetic heterogeneity of familial hemiplegic migraine. Am. J. Hum. Genet. (1994) 55(6):1166-1172.
  • OPHOFF RA, VAN EIJK R, SANDKUIJL LA et al.: Genetic heterogeneity of familial hemiplegic migraine. Genomics (1994) 22(1):21-26.
  • PEROUTKA SJ: Genetic basis of migraine. Clin. Neurosci. (1998) 5(1):34-37.
  • DIENER HC, LIMMROTH V: Advances in pharmacological treatment of migraine. Expert Opin. Investig. Drugs (2001) 10(10):1831-1845.
  • GOADSBY PJ: Advances in the understanding of headache. Br. Med. Bull. (2005) 73-74:83-92.
  • FERRARI MD, ROON KI, LIPTON RB, GOADSBY PJ: Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet (2001) 358(9294):1668-1675.
  • DAHLÖF CG, LINDE M, KEREKES E: Zolmitriptan nasal spray provides fast relief of migraine symptoms and is preferred by patients: a Swedish study of preference in clinical practice. J. Headache Pain (2004) 5(4):237-242.
  • SILBERSTEIN SD: Preventive treatment of migraine. Trends Pharmacol. Sci. (2006) 27(8):410-415.
  • TFELT-HANSEN P, HENRY P, MULDER LJ et al.: The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet (1995) 346(8980):923-926.
  • DIENER HC, BUSSONE G, DE LIANO H et al.: Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks. Cephalalgia (2004) 24(11):947-954.
  • GARCIA GD, GOFF JM Jr, HADRO NC, O'DONNELL SD, GREATOREX PS: Chronic ergot toxicity: a rare cause of lower extremity ischemia. J. Vasc. Surg. (2000) 31(6):1245-1247.
  • EVERS S, GRALOW I, BAUER B et al.: Sumatriptan and ergotamine overuse and drug-induced headache: a clinicoepidemiologic study. Clin. Neuropharmacol. (1999) 22(4):201-206.
  • LAMPL C, BUZATH A, YAZDI K, SANDOR PS: Ergot and triptan overuse in Austria – an evaluation of clinical data and cost. Cephalalgia (2002) 22(10):807-811.
  • GOADSBY PJ: Migraine: emerging treatment options for preventive and acute attack therapy. Expert Opin. Emerg. Drugs (2006) 11(3):419-427.
  • LEONARDI M, STEINER TJ, SCHER AT, LIPTON RB: The global burden of migraine: measuring disability in headache disorders with WHO's Classification of Functioning, Disability and Health (ICF). J. Headache Pain (2005) 6(6):429-440.
  • WESSMAN M, KALLELA M, KAUNISTO MA et al.: A susceptibility locus for migraine with aura, on chromosome 4q24. Am. J. Hum. Genet. (2002) 70(3):652-662.
  • BJORNSSON A, GUDMUNDSSON G, GUDFINNSSON E et al.: Localization of a gene for migraine without aura to chromosome 4q21. Am. J. Hum. Genet. (2003) 73(6):986-993.
  • GERVIL M, ULRICH V, KAPRIO J, OLESEN J, RUSSELL MB: The relative role of genetic and environmental factors in migraine without aura. Neurology (1999) 53(5):995-999.
  • GERVIL M, ULRICH V, KYVIK KO, OLESEN J, RUSSELL MB: Migraine without aura: a population-based twin study. Ann. Neurol. (1999) 46(4):606-611.
  • ULRICH V, GERVIL M, KYVIK KO, OLESEN J, RUSSELL MB: Evidence of a genetic factor in migraine with aura: a population-based Danish twin study. Ann. Neurol. (1999) 45(2):242-246.
  • RUSSELL MB, HILDEN J, SORENSEN SA, OLESEN J: Familial occurrence of migraine without aura and migraine with aura. Neurology (1993) 43(7):1369-1373.
  • RUSSELL MB, ISELIUS L, OLESEN J: Migraine without aura and migraine with aura are inherited disorders. Cephalalgia (1996) 16(5):305-309.
  • RUSSELL MB, OLESEN J: Increased familial risk and evidence of genetic factor in migraine. BMJ (1995) 311(7004):541-544.
  • NYHOLT DR, GILLESPIE NG, HEATH AC et al.: Latent class and genetic analysis does not support migraine with aura and migraine without aura as separate entities. Genet. Epidemiol. (2004) 26(3):231-244.
  • KALLELA M, WESSMAN M, HAVANKA H, PALOTIE A, FARKKILA M: Familial migraine with and without aura: clinical characteristics and co-occurrence. Eur. J. Neurol. (2001) 8(5):441-449.
  • LAUNER LJ, TERWINDT GM, FERRARI MD: The prevalence and characteristics of migraine in a population-based cohort: the GEM study. Neurology (1999) 53(3):537-542.
  • RASMUSSEN BK: Migraine and tension-type headache in a general population: precipitating factors, female hormones, sleep pattern and relation to lifestyle. Pain (1993) 53(1):65-72.
  • LIPTON RB, STEWART WF: Migraine in the United States: a review of epidemiology and health care use. Neurology (1993) 43(6 Suppl. 3):S6-S10.
  • NYHOLT DR, DAWKINS JL, BRIMAGE PJ et al.: Evidence for an X-linked genetic component in familial typical migraine. Hum. Mol. Genet. (1998) 7(3):459-463.
  • NYHOLT DR, CURTAIN RP, GRIFFITHS LR: Familial typical migraine: significant linkage and localization of a gene to Xq24-28. Hum. Genet. (2000) 107(1):18-23.
  • CARLSSON A, FORSGREN L, NYLANDER PO et al.: Identification of a susceptibility locus for migraine with and without aura on 6p12.2-p21.1. Neurology (2002) 59(11):1804-1807.
  • SORAGNA D, VETTORI A, CARRARO G et al.: A locus for migraine without aura maps on chromosome 14q21.2-q22.3. Am. J. Hum. Genet. (2003) 72(1):161-167.
  • NYHOLT DR, LEA RA, GOADSBY PJ, BRIMAGE PJ, GRIFFITHS LR: Familial typical migraine: linkage to chromosome 19p13 and evidence for genetic heterogeneity. Neurology (1998) 50(5):1428-1432.
  • JOUTEL A, BOUSSER MG, BIOUSSE V et al.: A gene for familial hemiplegic migraine maps to chromosome 19. Nat. Genet. (1993) 5(1):40-45.
  • LEA RA, SHEPHERD AG, CURTAIN RP et al.: A typical migraine susceptibility region localizes to chromosome 1q31. Neurogenetics (2002) 4(1):17-22.
  • CADER ZM, NOBLE-TOPHAM S, DYMENT DA et al.: Significant linkage to migraine with aura on chromosome 11q24. Hum. Mol. Genet. (2003) 12(19):2511-2517.
  • CUTRER FM, MOSKOWITZ MA: Wolff Award 1996. The actions of valproate and neurosteroids in a model of trigeminal pain. Headache (1996) 36(10):579-585.
  • RUSSO L, MARIOTTI P, SANGIORGI E et al.: A new susceptibility locus for migraine with aura in the 15q11-q13 genomic region containing three GABA-A receptor genes. Am. J. Hum. Genet. (2005) 76(2):327-333.
  • LEA RA, NYHOLT DR, CURTAIN RP et al.: A genome-wide scan provides evidence for loci influencing a severe heritable form of common migraine. Neurogenetics (2005) 6(2):67-72.
  • NYHOLT DR, MORLEY KI, FERREIRA MA et al.: Genomewide significant linkage to migrainous headache on chromosome 5q21. Am. J. Hum. Genet. (2005) 77(3):500-512.
  • ANTTILA V, KALLELA M, OSWELL G et al.: Trait components provide tools to dissect the genetic susceptibility of migraine. Am. J. Hum. Genet. (2006) 79(1):85-99.
  • PARDO J, CARRACEDO A, MUNOZ I et al.: Genetic markers: association study in migraine. Cephalalgia (1995) 15(3):200-204.
  • NYHOLT DR, CURTAIN RP, GAFFNEY PT et al.: Migraine association and linkage analyses of the human 5-hydroxytryptamine (5HT2A) receptor gene. Cephalalgia (1996) 16(7):463-467.
  • FANCIULLACCI M, ALESSANDRI M, DEL ROSSO A: Dopamine involvement in the migraine attack. Funct. Neurol. (2000) 15(Suppl. 3):171-181.
  • DEL ZOMPO M: Dopaminergic hypersensitivity in migraine: clinical and genetic evidence. Funct. Neurol. (2000) 15(Suppl. 3):163-170.
  • HEINZ A, GOLDMAN D, JONES DW et al.: Genotype influences in vivo dopamine transporter availability in human striatum. Neuropsychopharmacology (2000) 22(2):133-139.
  • MOCHI M, CEVOLI S, CORTELLI P et al.: A genetic association study of migraine with dopamine receptor 4, dopamine transporter and dopamine-β-hydroxylase genes. Neurol. Sci. (2003) 23(6):301-305.
  • DEL ZOMPO M, CHERCHI A, PALMAS MA et al.: Association between dopamine receptor genes and migraine without aura in a Sardinian sample. Neurology (1998) 51(3):781-786.
  • SHEPHERD AG, LEA RA, HUTCHINS C et al.: Dopamine receptor genes and migraine with and without aura: an association study. Headache (2002) 42(5):346-351.
  • MAUDE S, CURTIN J, BREEN G et al.: The -141C Ins/Del polymorphism of the dopamine D2 receptor gene is not associated with either migraine or Parkinson's disease. Psychiatry Genet. (2001) 11(1):49-52.
  • LEA RA, DOHY A, JORDAN K et al.: Evidence for allelic association of the dopamine β-hydroxylase gene (DBH) with susceptibility to typical migraine. Neurogenetics (2000) 3(1):35-40.
  • PEROUTKA SJ, WILHOIT T, JONES K: Clinical susceptibility to migraine with aura is modified by dopamine D2 receptor (DRD2) NcoI alleles. Neurology (1997) 49(1):201-206.
  • ANTHONY M: Biochemical indices of sympathetic activity in migraine. Cephalalgia (1981) 1(2):83-89.
  • EMIN ERDAL M, HERKEN H, YILMAZ M, BAYAZIT YA: Significance of the catechol-O-methyltransferase gene polymorphism in migraine. Brain Res. Mol. Brain Res. (2001) 94(1-2):193-196.
  • HAGEN K, PETTERSEN E, STOVNER LJ, SKORPEN F, ZWART JA: The association between headache and Val158Met polymorphism in the catechol-O-methyltransferase gene: the HUNT Study. J. Headache Pain (2006) 7(2):70-74.
  • MOSSNER R, FREITAG CM, MARZINIAK M et al.: The functional Val158Met variant of the COMT gene is not associated with migraine with or without aura. J. Headache Pain (2006) 7(3):165-166.
  • ANTHONY M, HINTERBERGER H, LANCE JW: Plasma serotonin in migraine and stress. Arch. Neurol. (1967) 16(5):544-552.
  • DALSGAARD-NIELSEN T, GENEFKE IK: Serotonin (5-hydroxytryptamine) release and uptake in platelets from healthy persons and migrainous patients in attack-free intervals. Headache (1974) 14(1):26-32.
  • KIMBALL RW, FRIEDMAN AP, VALLEJO E: Effect of serotonin in migraine patients. Neurology (1960) 10:107-111.
  • CHUGANI DC, NIIMURA K, CHATURVEDI S et al.: Increased brain serotonin synthesis in migraine. Neurology (1999) 53(7):1473-1479.
  • MOSKOWITZ MA: Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol. Sci. (1992) 13(8):307-311.
  • BREWERTON TD, MURPHY DL, MUELLER EA, JIMERSON DC: Induction of migrainelike headaches by the serotonin agonist m-chlorophenylpiperazine. Clin. Pharmacol. Ther. (1988) 43(6):605-609.
  • TERRON JA: Involvement of the 5-HT7 receptor in craniovascular vasodilatation: potential impact in migraine. Proc. West Pharmacol. Soc. (1998) 41:247-251.
  • TERRON JA: Is the 5-HT(7) receptor involved in the pathogenesis and prophylactic treatment of migraine? Eur. J. Pharmacol. (2002) 439(1-3):1-11.
  • TERRON JA, FALCON-NERI A: Pharmacological evidence for the 5-HT7 receptor mediating smooth muscle relaxation in canine cerebral arteries. Br. J. Pharmacol. (1999) 127(3):609-616.
  • RACCHI M, LEONE M, PORRELLO E et al.: Familial migraine with aura: Association study with 5-HT1B/1D, 5-HT2C, and hSERT polymorphisms. Headache (2004) 44:311-317.
  • BURNET PW, HARRISON PJ, GOODWIN GM et al.: Allelic variation in the serotonin 5-HT2C receptor gene and migraine. Neuroreport (1997) 8(12):2651-2653.
  • ERDAL ME, HERKEN H, YILMAZ M, BAYAZIT YA: Association of the T102C polymorphism of 5-HT2A receptor gene with aura in migraine. J. Neurol. Sci. (2001) 188(1-2):99-101.
  • JOHNSON MP, LEA RA, CURTAIN RP, MACMILLAN JC, GRIFFITHS LR: An investigation of the 5-HT2C receptor gene as a migraine candidate gene. Am. J. Med. Genet. (2003) 117B(1):86-89.
  • JUHASZ G, ZSOMBOK T, LASZIK A et al.: Association analysis of 5-HTTLPR variants, 5-HT2A receptor gene 102T/C polymorphism and migraine. J. Neurogenet. (2003) 17(2-3):231-240.
  • BUCHWALDER A, WELCH SK, PEROUTKA SJ: Exclusion of 5-HT2A and 5-HT2C receptor genes as candidate genes for migraine. Headache (1996) 36(4):254-258.
  • JOHNSON MP, GRIFFITHS LR: A genetic analysis of serotonergic biosynthetic and metabolic enzymes in migraine using a DNA pooling approach. J. Hum. Genet. (2005) 50(12):607-610.
  • MARZINIAK M, MOSSNER R, BENNINGHOFF J et al.: Association analysis of the functional monoamine oxidase A gene promotor polymorphism in migraine. J. Neural Transm. (2004) 111(5):603-609.
  • KOTANI K, SHIMOMURA T, SHIMOMURA F, IKAWA S, NANBA E: A polymorphism in the serotonin transporter gene regulatory region and frequency of migraine attacks. Headache (2002) 42(9):893-895.
  • OGILVIE AD, RUSSELL MB, DHALL P et al.: Altered allelic distributions of the serotonin transporter gene in migraine without aura and migraine with aura. Cephalalgia (1998) 18(1):23-26.
  • YILMAZ M, ERDAL ME, HERKEN H et al.: Significance of serotonin transporter gene polymorphism in migraine. J. Neurol. Sci. (2001) 186(1-2):27-30.
  • MATTSSON P, BJELFMAN C, LUNDBERG PO, RANE A: Cytochrome P450 2D6 and glutathione S-transferase M1 genotypes and migraine. Eur. J. Clin. Invest. (2000) 30(4):367-371.
  • KUSUMI M, ISHIZAKI K, KOWA H et al.: Glutathione S-transferase polymorphisms: susceptibility to migraine without aura. Eur. Neurol. (2003) 49(4):218-222.
  • BUZZI MG, TASSORELLI C, NAPPI G: Peripheral and central activation of trigeminal pain pathways in migraine: data from experimental animal models. Cephalalgia (2003) 23(Suppl. 1):1-4.
  • LEE TJ: Nitric oxide and the cerebral vascular function. J. Biomed. Sci. (2000) 7(1):16-26.
  • MARTELLETTI P, BRIOLI G, LULLI P et al.: Tumor necrosis factor B gene polymorphism contributes to susceptibility to migraine without aura. J. Headache Pain (2000) 2:119-122.
  • RAINERO I, GRIMALDI LM, SALANI G et al.: Association between the tumor necrosis factor-α-308 G/A gene polymorphism and migraine. Neurology (2004) 62(1):141-143.
  • COLSON NJ, LEA RA, QUINLAN S, MACMILLAN J, GRIFFITHS LR: The estrogen receptor 1 G594A polymorphism is associated with migraine susceptibility in two independent case/control groups. Neurogenetics (2004) 5:129-133.
  • COLSON NJ, LEA RA, QUINLAN S, MACMILLAN J, GRIFFITHS LR: Investigation of hormone receptor genes in migraine. Neurogenetics (2005) 6(1):17-23.
  • GRECO B, ALLEGRETTO EA, TETEL MJ, BLAUSTEIN JD: Coexpression of ER β with ER α and progestin receptor proteins in the female rat forebrain: effects of estradiol treatment. Endocrinology (2001) 142(12):5172-5181.
  • TZOURIO C, EL AMRANI M, POIRIER O et al.: Association between migraine and endothelin type A receptor (ETA-231 A/G) gene polymorphism. Neurology (2001) 56(10):1273-1277.
  • HASSELBLATT M, KOHLER J, VOLLES E, EHRENREICH H: Simultaneous monitoring of endothelin-1 and vasopressin plasma levels in migraine. Neuroreport (1999) 10(2):423-425.
  • GALLAI V, SARCHIELLI P, FIRENZE C et al.: Endothelin 1 in migraine and tension-type headache. Acta Neurol. Scand. (1994) 89(1):47-55.
  • KALLELA M, FARKKILA M, SAIJONMAA O, FYHRQUIST F: Endothelin in migraine patients. Cephalalgia (1998) 18(6):329-332.
  • PATERNA S, DI PASQUALE P, COTTONE C et al.: Migraine without aura and ACE-gene deletion polymorphism: is there a correlation? Preliminary findings. Cardiovasc. Drugs Ther. (1997) 11(4):603-604.
  • KOWA H, FUSAYASU E, IJIRI T et al.: Association of the insertion/deletion polymorphism of the angiotensin I-converting enzyme gene in patients of migraine with aura. Neurosci. Lett. (2005) 374(2):129-131.
  • RIGAT B, HUBERT C, ALHENC-GELAS F et al.: An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J. Clin. Invest. (1990) 86(4):1343-1346.
  • PATERNA S, DI PASQUALE P, D'ANGELO A et al.: Angiotensin-converting enzyme gene deletion polymorphism determines an increase in frequency of migraine attacks in patients suffering from migraine without aura. Eur. Neurol. (2000) 43(3):133-136.
  • LEA RA, OVCARIC M, SUNDHOLM J et al.: Genetic variants of angiotensin converting enzyme and methylenetetrahydrofolate reductase may act in combination to increase migraine susceptibility. Brain Res. Mol. Brain Res. (2005) 136(1-2):112-117.
  • KARA I, SAZCI A, ERGUL E, KAYA G, KILIC G: Association of the C677T and A1298C polymorphisms in the 5,10 methylenetetrahydrofolate reductase gene in patients with migraine risk. Brain Res. Mol. Brain Res. (2003) 111(1-2):84-90.
  • KOWA H, YASUI K, TAKESHIMA T et al.: The homozygous C677T mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for migraine. Am. J. Med. Genet. (2000) 96(6):762-764.
  • SCHER AI, TERWINDT GM, VERSCHUREN WM et al.: Migraine and MTHFR C677T genotype in a population-based sample. Ann. Neurol. (2006) 59(2):372-375.
  • KAUNISTO MA, KALLELA M, HAMALAINEN E et al.: Testing of variants of the MTHFR and ESR1 genes in 1798 Finnish individuals fails to confirm the association with migraine with aura. Cephalalgia (2006) 26(12):1462-1472.
  • TIETJEN GE: The relationship of migraine and stroke. Neuroepidemiology (2000) 19(1):13-19.
  • SZOLNOKI Z, SOMOGYVARI F, KONDACS A, SZABO M, FODOR L: Evaluation of the interactions of common genetic mutations in stroke subtypes. J. Neurol. (2002) 249(10):1391-1397.
  • LEA RA, OVCARIC M, SUNDHOLM J SOLYOM L, MACMILLAN J, GRIFFITHS LR: Genetic variants of angiotensin converting enzyme and methylene tetrahydrofolate reductase may act in combination to increase migraine susceptibility. Brain Res. Mol. Brain Res. (2005) 136(1-2)112-117.
  • THOMSEN LL, OLESEN J: Nitric oxide theory of migraine. Clin. Neurosci. (1998) 5(1):28-33.
  • BRUHWYLER J, CHLEIDE E, LIEGEOIS JF, CARREER F: Nitric oxide: a new messenger in the brain. Neurosci. Biobehav. Rev. (1993) 17(4):373-384.
  • BORRONI B, RAO R, LIBERINI P et al.: Endothelial nitric oxide synthase (Glu298Asp) polymorphism is an independent risk factor for migraine with aura. Headache (2006) 46(10):1575-1579.
  • MOCHI M, CEVOLI S, CORTELLI P et al.: Investigation of an LDLR gene polymorphism (19p13.2) in susceptibility to migraine without aura. J. Neurol. Sci. (2003) 213(1-2):7-10.
  • MCCARTHY LC, HOSFORD DA, RILEY JH et al.: Single-nucleotide polymorphism alleles in the insulin receptor gene are associated with typical migraine. Genomics (2001) 78(3):135-149.
  • SCHRADER H, STOVNER LJ, HELDE G, SAND T, BOVIM G: Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. BMJ (2001) 322(7277):19-22.
  • BENDER WI: ACE inhibitors for prophylaxis of migraine headaches. Headache (1995) 35(8):470-471.
  • TRONVIK E, STOVNER LJ, HELDE G, SAND T, BOVIM G: Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA (2003) 289(1):65-69.
  • RIGAT B, HUBERT C, ALHENC-GELAS F et al.: An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J. Clin. Invest. (1990) 86(4):1343-1346.
  • TIRET L, RIGAT B, VISVIKIS S et al.: Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am. J. Hum. Genet. (1992) 51(1):197-205.
  • PATERNA S, DI PASQUALE P, D'ANGELO A et al.: Angiotensin-converting enzyme gene deletion polymorphism determines an increase in frequency of migraine attacks in patients suffering from migraine without aura. Eur. Neurol. (2000) 43(3):133-136.
  • FROSST P, BLOM HJ, MILOS R et al.: A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat. Genet. (1995) 10(1):111-113.
  • DAS UN: Folic acid says NO to vascular diseases. Nutrition (2003) 19(7-8):686-692.
  • LEE BJ, LIN PT, LIAW YP et al.: Homocysteine and risk of coronary artery disease: folate is the important determinant of plasma homocysteine concentration. Nutrition (2003) 19(7-8):577-583.
  • HYNDMAN ME, MANNS BJ, SNYDER FF et al.: Vitamin B12 decreases, but does not normalize, homocysteine and methylmalonic acid in end-stage renal disease: a link with glycine metabolism and possible explanation of hyperhomocysteinemia in end-stage renal disease. Metabolism (2003) 52(2):168-172.
  • SILBERSTEIN SD: Topiramate in migraine prevention: evidence-based medicine from clinical trials. Neurol. Sci. (2004) 25(Suppl. 3):S244-S245.
  • KLAPPER J: Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia (1997) 17(2):103-108.
  • HERING-HANIT R: Baclofen for prevention of migraine. Cephalalgia (1999) 19(6):589-591.
  • WELCH KM, CHABI E, BARTOSH K, ACHAR VS, MEYER JS: Cerebrospinal fluid g aminobutyric acid levels in migraine. BMJ (1975) 3(5982):516-517.
  • RAMADAN NM: The link between glutamate and migraine. CNS Spectr. (2003) 8(6):446-449.
  • MARTINEZ F, CASTILLO J, RODRIGUEZ JR, LEIRA R, NOYA M: Neuroexcitatory amino acid levels in plasma and cerebrospinal fluid during migraine attacks. Cephalalgia (1993) 13(2):89-93.
  • GALLAI V, ALBERTI A, GALLAI B et al.: Glutamate and nitric oxide pathway in chronic daily headache: evidence from cerebrospinal fluid. Cephalalgia (2003) 23(3):166-174.
  • MARTIN VT, BEHBEHANI M: Ovarian hormones and migraine headache: understanding mechanisms and pathogenesis – Part I. Headache (2006) 46(1):3-23.
  • PECINS-THOMPSON M, BROWN NA, BETHEA CL: Regulation of serotonin re-uptake transporter mRNA expression by ovarian steroids in rhesus macaques. Brain Res. Mol. Brain Res. (1998) 53(1-2):120-129.
  • PECINS-THOMPSON M, BROWN NA, KOHAMA SG, BETHEA CL: Ovarian steroid regulation of tryptophan hydroxylase mRNA expression in rhesus macaques. J. Neurosci. (1996) 16(21):7021-7029.
  • SMITH LJ, HENDERSON JA, ABELL CW, BETHEA CL: Effects of ovarian steroids and raloxifene on proteins that synthesize, transport, and degrade serotonin in the raphe region of macaques. Neuropsychopharmacology (2004) 29(11):2035-2045.
  • HERBISON AE, SIMONIAN SX, THANKY NR, BICKNELL RJ: Oestrogen modulation of noradrenaline neurotransmission. Novartis Found. Symp. (2000) 230:74-85; discussion 85-93.
  • PAU KY, HESS DL, KOHAMA S et al.: Oestrogen upregulates noradrenaline release in the mediobasal hypothalamus and tyrosine hydroxylase gene expression in the brainstem of ovariectomized rhesus macaques. J. Neuroendocrinol. (2000) 12(9):899-909.
  • KARKANIAS GB, ANSONOFF MA, ETGEN AM: Estradiol regulation of α1b-adrenoceptor mRNA in female rat hypothalamus-preoptic area. J. Neuroendocrinol. (1996) 8(6):449-455.
  • KARKANIAS GB, ETGEN AM: Estradiol attenuates α2-adrenoceptor-mediated inhibition of hypothalamic norepinephrine release. J. Neurosci. (1993) 13(8):3448-3455.
  • KARKANIAS GB, PETITTI N, ETGEN AM: Progesterone attenuation of α1-adrenergic receptor stimulation of phosphoinositol hydrolysis in hypothalamus of estrogen-primed female rats. Endocrinology (1995) 136(5):1993-1999.
  • SHUGHRUE PJ, MERCHENTHALER I: Estrogen is more than just a “sex hormone”: novel sites for estrogen action in the hippocampus and cerebral cortex. Front. Neuroendocrinol. (2000) 21(1):95-101.
  • KELLY MJ, LOOSE MD, RONNEKLEIV OK: Estrogen suppresses μ-opioid- and GABAB-mediated hyperpolarization of hypothalamic arcuate neurons. J. Neurosci. (1992) 12(7):2745-2750.
  • TWYMAN RE, MACDONALD RL: Neurosteroid regulation of GABAA receptor single-channel kinetic properties of mouse spinal cord neurons in culture. J. Physiol. (1992) 456:215-245.
  • EPPERSON CN, HAGA K, MASON GF et al.: Cortical γ-aminobutyric acid levels across the menstrual cycle in healthy women and those with premenstrual dysphoric disorder: a proton magnetic resonance spectroscopy study. Arch. Gen. Psychiatry (2002) 59(9):851-858.
  • KRAUSE DN, DUCKLES SP, PELLIGRINO DA: Influence of sex steroid hormones on cerebrovascular function. J. Appl. Physiol. (2006) 101(4):1252-1261.
  • NAPPI RE, SANCES G, BRUNDU B et al.: Estradiol supplementation modulates neuroendocrine response to m-chlorophenylpiperazine in menstrual status migrainosus triggered by oral contraception-free interval. Hum. Reprod. (2005) 20(12):3423-3428.
  • JUNG AC, STAIGER T, SULLIVAN M: The efficacy of selective serotonin reuptake inhibitors for the management of chronic pain. J. Gen. Intern. Med. (1997) 12(6):384-389.
  • SMITS K, SMITS L, PEETERS F et al.: Serotonin transporter polymorphisms and the occurrence of adverse events during treatment with selective serotonin reuptake inhibitors. Int. Clin. Psychopharmacol. (2007) 22(3):137-143.
  • SMITS KM, SMITS LJ, SCHOUTEN JS et al.: Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: a systematic review. Mol. Psychiatry (2004) 9(5):433-441.
  • MOJA PL, CUSI C, STERZI RR, CANEPARI C: Selective serotonin re-uptake inhibitors (SSRIs) for preventing migraine and tension-type headaches. Cochrane Database Syst. Rev. (2005) (3):CD002919.
  • GONDA X, RIHMER Z, JUHASZ G, ZSOMBOK T, BAGDY G: High anxiety and migraine are associated with the s allele of the 5HTTLPR gene polymorphism. Psychiatry Res. (2007) 149(1-3):261-266.
  • GENAZZANI AR, STOMATI M, MORITTU A et al.: Progesterone, progestagens and the central nervous system. Hum. Reprod. (2000) 15(Suppl. 1):14-27.
  • HOGSKILDE S, NIELSEN JW, CARL P, SORENSEN MB: Pregnanolone emulsion. A new steroid preparation for intravenous anesthesia: an experimental study in mice. Anesthesia (1987) 42(6):586-590.
  • BACKSTROM T, GEE KW, LAN N, SORENSEN M, WAHLSTROM G: Steroids in relation to epilepsy and anesthesia. Ciba Found. Symp. (1990) 153:225-230; discussion 230-229.
  • GRUBER CJ, HUBER JC: Differential effects of progestins on the brain. Maturitas (2003) 46(Suppl. 1):S71-S75.
  • LIMMROTH V, LEE WS, MOSKOWITZ MA: GABAA-receptor-mediated effects of progesterone, its ring-A-reduced metabolites and synthetic neuroactive steroids on neurogenic oedema in the rat meninges. Br. J. Pharmacol. (1996) 117(1):99-104.
  • PETITCLERC M, BEDARD PJ, DI PAOLO T: Progesterone releases dopamine in male and female rat striatum: a behavioral and microdialysis study. Prog. Neuropsychopharmacol. Biol. Psychiatry (1995) 19(3):491-497.
  • SINCHAK K, MICEVYCH PE: Progesterone blockade of estrogen activation of μ-opioid receptors regulates reproductive behavior. J. Neurosci. (2001) 21(15):5723-5729.
  • REDDY DS, APANITES LA: Anesthetic effects of progesterone are undiminished in progesterone receptor knockout mice. Brain Res. (2005) 1033(1):96-101.
  • RUPPRECHT R, REUL JM, TRAPP T et al.: Progesterone receptor-mediated effects of neuroactive steroids. Neuron (1993) 11(3):523-530.
  • AMIR BY, YAACOV B, GUY B et al.: Headaches in women undergoing in vitro fertilization and embryo-transfer treatment. Headache (2005) 45(3):215-219.
  • SOMERVILLE BW: The role of estradiol withdrawal in the etiology of menstrual migraine. Neurology (1972) 22(4):355-365.
  • SOMERVILLE BW: Estrogen-withdrawal migraine. I. Duration of exposure required and attempted prophylaxis by premenstrual estrogen administration. Neurology (1975) 25(3):239-244.
  • LICHTEN EM, LICHTEN JB, WHITTY A, PIEPER D: The confirmation of a biochemical marker for women's hormonal migraine: the depo-estradiol challenge test. Headache (1996) 36(6):367-371.
  • STEIN GS: Headaches in the first post partum week and their relationship to migraine. Headache (1981) 21(5):201-205.
  • MACGREGOR EA: Oestrogen and attacks of migraine with and without aura. Lancet Neurol. (2004) 3(6):354-361.
  • EPSTEIN MT, HOCKADAY JM, HOCKADAY TD: Migraine and reporoductive hormones throughout the menstrual cycle. Lancet (1975) 1(7906):543-548.
  • CALHOUN AH: A novel specific prophylaxis for menstrual-associated migraine. South Med. J. (2004) 97(9):819-822.
  • DENNERSTEIN L, MORSE C, BURROWS G et al.: Menstrual migraine: a double-blind trial of percutaneous estradiol. Gynecol. Endocrinol. (1988) 2(2):113-120.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.